Ortho Regenerative Technologies Begins Trading On The CSE
Published: Oct 10, 2017
KIRKLAND, QC, Oct. 10, 2017 /CNW/ - Ortho Regenerative Technologies Inc. ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, will begin trading today on the Canadian Securities Exchange ("CSE") under the stock symbol "ORTH."
Ortho RTi's public listing follows a series of recent accomplishments and advancements:
- In March 2017, four key scientific studies validating the Corporation's technology's ability to improve the repair of three distinct joint tissues - the rotator cuff tendon, the meniscus and articular cartilage - were reviewed by external experts and selected for presentation at the prestigious Annual Orthopaedic Research Society ("ORS") Annual Meeting in San Diego, CA.
- In August 2017, accomplished pharmaceutical industry executive, Francois-Xavier Lacasse, Ph.D, joined Ortho RTi as Vice President of Product Development. Bringing over 20 years of drug development experience and extensive senior consulting and leadership experience, Dr. Lacasse is expected to be a tremendous asset as the Corporation continues to advance its proprietary biopolymer platform.
- In September 2017, Ortho RTi announced that its Chief Scientific Officer, Michael Buschman, a world-class researcher who has made fundamental contributions to the fields of biomechanics, biomaterials and nanomedicine, was appointed as the Bioengineering Chair, Professor and Eminent Scholar at George Mason University in Fairfax, Virginia.
- Two weeks ago, the Corporation appointed well-known global sports and entertainment executive, Tom Wright, to its Board of Directors. Mr. Wright's extensive experience advising companies, combined with his well-earned reputation for creativity, drive and integrity, and his strong network of contacts in both amateur and professional sports, should prove to be a tremendous asset to Ortho RTi.
In addition to these developments, Ortho RTi has grown its total headcount to 19, including 13 scientists under contract, obtained approximately $1 million non-dilutive Prima Grant, and over $12 million in funding for research and development has been invested in the technology to date.
"We are extremely proud of the progress the Ortho RTi team has made towards meeting the rapidly growing unmet medical needs in a global market." said Ortho RTi's Executive Chairman and CEO, Dr. Brent Norton. "I am confident that these recent developments will firmly positon us, as we continue to advance our proprietary biopolymer platform."
About Ortho Regenerative Technologies Inc.
Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.
This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.
SOURCE Ortho Regenerative Technologies Inc.